U.S. biosimilar drugs may welcome ten years of continuous growth

Author: Qingwa

"There was a view that the approval of biosimilar drugs for the market will not only significantly reduce the price of original research drugs, but also bring serious homogeneity competition to biosimilar drugs

Ronny Gal, an analyst at Bernstein in the United States, said in a quarterly study on the performance and prospects of biosimilars, "Although it may not be obvious on the surface, biosimilars have always been the main force in easing drug prices

"After the biosimilars are on the market, the winner is the customer/patient, saving approximately US$8.

Gal wrote that although the US biosimilars market has started slowly, its annualized market has reached approximately US$4 billion in the past three quarters

"The reason is that due to the continuous emergence of latecomers, the prices of early entrants have been forced to fall, and the competition from innovative drugs has intensified.

A typical example is the Remicade biosimilar Inflectra, which Pfizer took the lead in the market

Nevertheless, sales data show that the original research products are still the dominant force in the market

Looking ahead, as the biosimilars of Roche's macular degeneration drug Lucentis and AbbVie Humira will be launched in 2023, analysts believe that the US biosimilar market will experience moderate growth and will usher in a ten-year period of continuous growth

Regarding the prospect analysis of some companies in the field of biosimilar drugs, analysts believe that Pfizer will benefit from the biosimilar drugs of Remicade and Avastin in the short term; Amgen is expected to increase revenue with Humira biosimilar drugs in 2023; and integration Later Huizhi is most likely to need to change its strategy; as for Teva, it largely depends on its partnership with Alvotech

Reference: Biosims generating $8B+ in annual savings, and a'decade of growth' is ahead: analyst